×
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
Bekker P., Keshav S., Johnson D., Schall T.
DOI
10.1097/00054725-200912002-00030
Type
Conference paper
Publication Date
12/2009
Volume
15
Pages
S11 - S11